Edition:
United Kingdom

Ono Pharmaceutical Co Ltd (4528.T)

4528.T on Tokyo Stock Exchange

2,028JPY
7:00am BST
Change (% chg)

¥-7 (-0.34%)
Prev Close
¥2,035
Open
¥2,035
Day's High
¥2,035
Day's Low
¥2,011
Volume
1,691,400
Avg. Vol
1,775,864
52-wk High
¥3,430
52-wk Low
¥1,822

Latest Key Developments (Source: Significant Developments)

Bayer, Bristol-Myers Squibb And Ono Pharmaceutical Enter Into A Clinical Collaboration Agreement
Thursday, 18 Jul 2019 

July 18 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>::BAYER, BRISTOL-MYERS SQUIBB AND ONO PHARMACEUTICAL ENTER INTO A CLINICAL COLLABORATION AGREEMENT TO INVESTIGATE STIVARGA® (REGORAFENIB) AND OPDIVO® (NIVOLUMAB) AS COMBINATION THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER.BRISTOL-MYERS SQUIBB CO - COMPANIES PLAN INDICATION-SEEKING TRIAL.BRISTOL-MYERS SQUIBB CO - FURTHER TERMS OF CLINICAL COLLABORATION WERE NOT DISCLOSED..BRISTOL-MYERS - COMBINATION OF REGORAFENIB, NIVOLUMAB VERSUS. REGORAFENIB TO BE EVALUATED IN PATIENTS WITH MICRO-SATELLITE METASTATIC COLORECTAL CANCER.BRISTOL-MYERS - DATA SEEN IN REGONIVO WARRANT FURTHER EXPLORATION OF COMBINATION OF REGORAFENIB AND NIVOLUMAB IN PATIENTS WITH COLORECTAL CANCER.  Full Article

Ono Pharmaceutical Co Ltd - To Buy Back Up To 2.92% Of Own Shares Worth 30 Billion Yen And Cancel Them On Oct. 31
Thursday, 30 May 2019 

Ono Pharmaceutical Co Ltd <4528.T>::ONO PHARMACEUTICAL CO LTD - TO BUY BACK UP TO 2.92% OF OWN SHARES WORTH 30 BILLION YEN AND CANCEL THEM ON OCT. 31.  Full Article

Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it entered into license agreement with Bristol-Myers Squibb Company (BMS)for Prostaglandin E2 receptor antagonists relating to Immuno-Oncology programs .Under the terms of this agreement, BMS is granted the rights to develop and commercialize ONO-4578 and other compounds from PGE2 receptor antagonist programs worldwide, except Japan, South Korea, Taiwan, China and Association of South-East Asian Nations (ASEAN)countries.In accordance with this agreement, ONO receives an upfront payment of $40 million from BMS.ONO will also receive subsequent clinical, regulatory and sales-based milestone payments, as well as royalties based on sales of the products in the countries where ONO granted BMS the rights for development and commercialization.  Full Article

Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.BRISTOL-MYERS SQUIBB-WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING,COMMERCIALIZATION OF ONO-4578,OTHER PGE(2) RECEPTOR ANTAGONIST PRODUCTS.  Full Article

Ono Pharmaceutical completes retirement of treasury shares
Tuesday, 31 Oct 2017 

Oct 31(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says it completed retirement of 45.9 million shares (7.8 percent of outstanding) on Oct. 31.Says the total shares outstanding 543.3 million shares after the retirement.  Full Article

Nikkei flat as trade woes, strong yen saps risk appetite; SoftBank Group falls

TOKYO, June 4 Japan's Nikkei ended nearly flat in choppy trade on Tuesday as festering trade tensions and a stronger yen curbed risk appetite, while extended losses for index-heavy SoftBank Group added to the overall pressure on the market.